The Daily Aus Summer series: The young Aussies using Ozempic
Dec 28, 2025
Dr. Michael Bonning, Chair of Public Health at the Australian Medical Association and practicing GP, dives into the world of GLP-1 medications like Ozempic. He explains how these drugs influence insulin and weight management. The conversation reveals personal success stories, alongside troubling reports of adverse effects, including mental health risks linked to their use. Dr. Bonning also discusses the ethical implications of prescribing practices and the challenges surrounding telehealth in young Australians.
AI Snips
Chapters
Transcript
Episode notes
How GLP-1s Work And Why Demand Skyrocketed
- GLP-1 drugs like Ozempic (semaglutide) were developed for type 2 diabetes and work by improving insulin response and slowing gastric emptying.
- Their appetite-suppressing side effects led to widespread off-label weight-loss use and major demand beyond original indications.
One User’s Life Changed By Weight-Loss Medication
- Grace, 26, used Ozempic and Munjaro and lost over 17 kilos in six months while regaining confidence and mobility.
- She described the drugs as giving her control over compulsive food thoughts and ending constant 'food noise.'
Reported Side Effects Include GI And Mental-Health Risks
- TGA adverse-event reports for semaglutide products show gastrointestinal issues (including pancreatitis) dominate reports between Jan 2023–Jan 2025.
- Suicidal ideation also appears, highlighting less-known but serious possible harms that need more investigation.